

Tatjana Stankovic

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4205780/tatjana-stankovic-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19
papers

922
citations

10
h-index

22
g-index

22
ext. papers

1,135
ext. citations

7.4
avg, IF

3.24
L-index

#	Paper	IF	Citations
19	Signatures of TOP1 transcription-associated mutagenesis in cancer and germline.. <i>Nature</i> , 2022 ,	50.4	4
18	TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. <i>Blood</i> , 2021 , 137, 3064-3078	2.2	2
17	Reference charts of birth weight and birth length by gestational age in south east Serbian newborns: Preliminary results. <i>Vojnosanitetski Pregled</i> , 2021 , 78, 87-91	0.1	
16	Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. <i>Cancers</i> , 2021 , 13,	6.6	2
15	Potential role of IFN- γ and IL-5 in sepsis prediction of preterm neonates. <i>Open Medicine (Poland)</i> , 2021 , 16, 139-145	2.2	
14	Genetics in the era of targeted CLL therapy. <i>Blood</i> , 2020 , 135, 2333-2334	2.2	0
13	Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL. <i>Blood</i> , 2020 , 135, 411-428	2.2	9
12	Fetal chromosomal anomalies in southeast Serbia - single center cohort retrospective study. <i>Genetika</i> , 2019 , 51, 157-166	0.6	
11	ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks. <i>Nature Communications</i> , 2019 , 10, 87	17.4	73
10	CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. <i>Nature</i> , 2018 , 559, 285-289	50.4	178
9	USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. <i>Blood</i> , 2017 , 130, 156-166	2.2	41
8	ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. <i>Blood</i> , 2016 , 127, 582-95	2.2	154
7	NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. <i>Oncotarget</i> , 2016 , 7, 68513-68526	3.3	32
6	T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice. <i>DMM Disease Models and Mechanisms</i> , 2015 , 8, 1401-12	4.1	5
5	ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. <i>Haematologica</i> , 2012 , 97, 142-6	6.6	26
4	Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2008 , 136, 187-92	0.2	17
3	Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5448-57	2.2	208

2	Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling. <i>Blood</i> , 2004 , 104, 1465-73	2.2	49
1	Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. <i>Blood</i> , 2002 , 99, 300-9	2.2	121